Arcus Biosciences Shares Rise 11% on AstraZeneca Partnership
October 29 2020 - 1:36PM
Dow Jones News
By Chris Wack
Arcus Biosciences Inc. shares were up 11% at $22.67 after the
company said it was in a collaboration with AstraZeneca to evaluate
domvanalimab in combination with Imfinzi durvalumab in a
registrational Phase 3 clinical trial in patients with unresectable
Stage III non-small cell lung cancer.
AstraZeneca's Imfinzi is the only immunotherapy approved for
patients with unresectable Stage III NSCLC. Results from a Phase 3
trial showed treatment with Imfinzi following chemotherapy and
radiation therapy led to unprecedented survival in unresectable
Stage III NSCLC, with an estimated 50% of patients surviving four
years versus 36% for CRT alone, and 35% of patients not progressing
after four years versus 20% for CRT alone.
Arcus is currently evaluating domvanalimab in a three-arm
randomized Phase 2 study for first-line treatment of PD-L1-high
metastatic NSCLC evaluating zimberelimab monotherapy, versus
domvanalimab with zimberelimab, versus domvanalimab plus
etrumadenant with zimberelimab.
Under the terms of the agreement, each company will retain
existing rights to their respective molecules and any future
commercial economics. AstraZeneca will conduct the trial, and each
company will supply its respective anti-cancer agent to support the
trial. The companies will share costs for the trial.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 29, 2020 13:21 ET (17:21 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024